News

updated on April 15^th, 2009

Alliance Biosecure announces its 2009 Call for Grant Applications
Paris, 14 April 2009
The Research Foundation Alliance BioSecure announces today its annual Call for Grant Applications for a total amount of  450,000 euros.More information on this website.

The Alliance BioSecure Foundation announces the results of it’s 2008 call for projects
Grants will be awarded on October 10th during the Prion 2008 meeting in Madrid

The foundation Alliance Biosecure announces the results of its call for projects 2007
Lille (France), Edinburgh (UK), 28 September 2007
Press release : The Foundation Alliance Biosecure announces today, both at EUROBIO forum in Lille and at Prion 2007 congress in Edinburgh, the results of its international call for projects 2007, launched on April 5th, and for which a total sum of 400,000 Euros was available. The selected projects are...

Alliance Biosecure officially launches its activities.
Senat, Paris, 5 April 2007
The Research Foundation Alliance BioSecure ("Biosafety Alliance Foundation") organizes today at the French Senate, Paris a press conference to communicate officially for the first time on its mission.

Alliance BioSecure

The Alliance BioSecure Research Foundation, recognised as a public utility in December 2006, has the objective “to progress the analysis, understanding and management of public health risk related to current or emerging microbiological agents, in particular prions” (article 1 of the statutes)

This Public Health mission shall be fulfilled:

• By regularly evaluating and communicating the risks associated with these agents through updating an epidemiological database and surveillance at a global level. These initiatives will assist risk prediction, which will be beneficial to the wider public.
• By contributing to an understanding of the mechanisms of virulence, pathogenicity, and transmissibility of these agents.
• By promoting the discovery of technological solutions related to the detection, elimination and inactivation of these agents in biological products for therapeutic use, physical material used during their production, material used in clinical investigation, and products destined for consumption.
• By, when possible, adding value to research results by developing new therapeutic approaches.
• By organising staff training and informing the wider public of the biological risks, their management, and more particularly their consequences on society and public health.